NEWARK, Calif., Nov. 11, 2021 /PRNewswire/ -- Protagonist
Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company")
today announced that Dinesh V.
Patel, Ph.D., President and Chief Executive Officer, will
present and host one-on-one meetings with investors at upcoming
healthcare investor conferences hosted by Jefferies and Piper Sandler.
Event: Jefferies London Healthcare Conference
Date: November 18, 2021
Time: 3 a.m. EST
Event: Piper Sandler 33rd
Annual Healthcare Conference
Date: November 22, 2021
Time: 10 a.m. EST
A webcast of the event will be available for 90 days on the
Investors section of the Protagonist Therapeutics website at
Protagonist Therapeutics is a biopharmaceutical company with
multiple peptide-based investigational new chemical entities in
different stages of development, all derived from the Company's
proprietary technology platform.
Protagonist's pipeline includes rusfertide (PTG-300), an
investigational, injectable hepcidin mimetic currently in a Phase 2
proof-of-concept clinical trial for polycythemia vera (PV), a Phase
2 study in PV subjects with high hematocrit levels, and a Phase 2
study for hereditary hemochromatosis. The Company plans to initiate
a single, global Phase 3 randomized, placebo-controlled trial
evaluating the efficacy and safety of a once weekly, subcutaneously
self-administered dose of rusfertide.
The Company is also evaluating an orally delivered,
gut-restricted alpha-4-beta-7 integrin specific antagonist peptide
(PN-943) currently in a Phase 2 study in adults with moderate to
severe active ulcerative colitis (UC). The Company is targeting
ulcerative colitis as the initial indication.
The Company has a worldwide license and collaboration agreement
with Janssen Biotech, Inc., for the development of oral peptide
IL-23 receptor antagonists. Compounds in development include PN-235
and PN-232, both second-generation oral interleukin-23 receptor
antagonist candidates. The Phase 1 study of PN-235 is
completed, and Janssen is expected to initiate a Phase 2 study in
psoriasis in early 2022. The Phase 1 study with PN-232 is in
progress, with study completion expected by mid-2022. Additional
research in IBD is expected to initiate in 2022.
Protagonist is headquartered in Newark, California.
For further information, please
View original content to download
SOURCE Protagonist Therapeutics, Inc.